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Abstract We studied the effect of lovastatin, a cholesterol low- 
ering drug, on the basal state of G-proteins in GH4C 1 cells. Our 
data show that the addition of lovastatin markedly decreased the 
amount of the ot-subunits of the Gs and Gi-proteins in the plasma 
membrane. The decrease of as was correlated with a decrease in 
adenylyl cyclase activity, and both effects were reverted by the 
presence of mevalonate. As the attachment of G protein subunits 
to the membrane is dependent on y-subunit prenylation, we as- 
sume that the mechanism through which lovastatin exerts its 
effects on G-proteins is the lack of mevalonate for the synthesis 
of prenyl residues. In conclusion, our data indicate that some of 
the effects of lovastatin are mediated through changes in the basal 
state of G-protein in the membrane and consequently on adenylyl 
cyclase activity. 
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1. Introduction 
Adenylyl cyclase (AC) activity is under a dual regulation by 
G-proteins that can couple cell surface receptors to stimulate 
(Gs) or inhibit (G~) ligands to the catalytic unit of AC [1]. Both 
Gs and Gi are heterotrimeric proteins. Each consists of a dis- 
tinct ~-subunit that can be ADP-ribosylated with CTX and 
PTX, respectively, and a highly conserved fl~'-dimer [2]. 
G-proteins transduce information from a variety of mem- 
brane receptors and photopigments to a less populous group 
of effectors that include AC, cyclic GMP phosphodiesterase, 
phospholipase C, and several ion channels. Of the three G- 
protein subunits the fl- and ?,-subunits do not dissociate under 
physiological conditions and thus behave ssentially as a mon- 
omer. Gfly is required for efficient coupling of G~-subunits o
cell surface receptors, and functions as a membrane anchor, 
which stabilizes the basal GDP-bound Gc~ for interaction with 
the appropriate cell surface receptor [3,4]. 
All the existing G7 structures i olated contain the consensus 
CAAX domain (C = cysteine; A = aliphatic amino acid; 
X = any amino acid) as their carboxyl-terminus. Retinal 71 and 
brain ;g2 proteins have been shown to contain farnesyl [5,6] and 
geranylgeranyl [7,8] modifications in the C-terminal cysteine 
residues, respectively. On the other hand, the G~ proteins of 
the G i subfamily are myristoylated [9] and members of the Gs 
and Gq subfamilies of ~ units are palmitoylated [10,11]. In 
addition, members of the G~ subfamily are both palmitoylated 
and myristoylated at separate sites [10]. Unlike myristoylation, 
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which is usually an irreversible cotranslational modification, 
palmitoylation is a dynamic posttranslational protein modifica- 
tion, and in each GTP cycle a palmitoyl residue is added and 
hydrolyzed from the c~s ubunit [12]. 
The prenyl residues necessaries for posttranslational modifi- 
cation of proteins are synthesized from mevalonate. Cultured 
cells in the presence of whole serum mainly derive their cholest- 
erol from plasma lipoproteins, and their mevalonate by synthe- 
sis from acetyl CoA because they maintain low levels of hydroxy- 
methyl glutaryl coenzyme A (HMG-CoA) reductase. In the 
absence of cholesterol in the medium, cells maintain high levels 
of HMG-CoA reductase to increase both mevalonate and 
cholesterol synthesis [13,14]. The discovery of potent inhibitors 
of HMG-CoA reductase has been of great therapeutic benefit 
to hypercholesterolemia patients. The prototype of these inhib- 
itors, lovastatin, has been throughly studied and much is known 
about its cholesterol-lowering mechanism. Little attention has 
been paid, however, to the mechanism(s) by which lovastatin 
inhibits DNA synthesis and cell proliferation. In recent years, 
the role of hormones that act through the cAMP signalling 
pathways on cellular growth has become vident [15], and func- 
tional abnormalities of Gc~s have been characterized in several 
human secretory tumors [16]; so we decided to study how lova- 
statin affects the basal steady-state of Gs and Gi proteins and 
their regulated effector AC in endocrine (GH4C0 cells. 
2. Materials and methods 
2.1. Materials 
32p was from New England Nuclear (Boston, MA). Lovastatin was 
kindly provided by Merck Sharp and Dohme Res. Lab. (Rahway, NJ). 
Culture media, sera and antibiotic were from Gibco (Grand Island, 
NY), and culture flasks and plates were purchased from Nunc 
(Roskilde, Denmark). Antibodies to Gc~ sand Gc~ were from Calbio- 
chem (Palo Alto, CA). All other reagents were obtained from Sigma 
(St. Louis, MO), Calbiochem orMerck and were of the maximal purity 
available. 
2.2. Cell culture and cellular treatments 
Pituitary GH4C 1 cells were grown in monolayers as previously de- 
scribed [17] in Dulbecco's modified Eagle's Medium supplemented with 
10% foetal calf serum (FCS) in a water saturated atmosphere of 5% CO2 
and 95% air. 
At the beginning of the experiments, the cells were rinsed with saline 
and incubated with fresh media containing 10% hurnan-lipoprotein 
deficient serum (h-LPDS) for 24 h at 37°C. After this preincubation 
period, the cells were rinsed and incubated with the different media s 
described in the figure legends for 48 h. 
Lovastatin was converted tothe lactone sodium salt as described by 
Kita et al. [18], and diluted in water (5 mM). Mevalono-lactone was 
diluted in water (10 raM). All of these compounds were added to the 
medium supplemented with 10% h-LPDS. 
At the end of the incubation, the cells were homogenized byfrozen 
in liquid nitrogen and thawed at 32°C for three times. The homogenates 
were kept on ice until assay. 
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2.3. Isolation of lipoprotein-deficient serum 
Human lipoprotein-deficient serum (h-LPDS) was prepared by ul- 
tracentrifugal flotation in potassium bromide [19] at 1.210 g/ml density 
[20]. After extensive dialysis against 50 mM Tris, 150 mM NaC1, 0.01% 
EDTA, pH 7.4, buffer, h-LPDS was sterilized by passage through a 
Millipore filter (Millex-GV; 0.22/tin) and kept frozen at -20°C. 
2.4. Adenylyl cyclase assay 
Incubations were performed at 32°C for 10 min in a final volume of 
50/.tl containing 0.1 mM [a-32p]ATP (approx. 10 x 106 cpm/assay), 2.0 
mM MgC12, 1.0 mM EDTA, 1.0 mM [3H]cAMP (approx. 15,000 cpm/ 
assay), 0.1% bovine serum albumin, a nucleoside triphosphate r gener- 
ating system (20 mM creatine phosphate, 26 U/ml creatine kinase, 25 
U/ml myokinase, 25 mM Tris-HC1, pH 7.6), 10/11 homogenate, 20/zM 
GTP and, when present: 10 mM NaF, 250 nM VIE 100/tM forskolin. 
After 10 min of incubation, the reaction was stopped by addition of 100 
/zl of stopping solution (10 mM ATP, 10 mM cAMP and 1% sodium 
dodecyl sulfate (SDS)). The [32p]cAMP formed was measured by a 
modification [21] of the method of Salomon et al. [22]. Values are 
expressed as pmol of cAMP generated per min per mg cell protein. 
2.5. ADP-ribosylation of G~ and G~ in cell homogenates 
CTX from Sigma (5 mg/ml) and PTX from Calbiochem (0.6 mg/ml) 
were first activated for 30 min at 32°C in 10 mM Tris-HC1, pH 7.6, 50 
mM dithiothreitol. The ADP-ribosylations were performed as de- 
scribed by Ribeiro-Neto et al. [23] using 5/lg activated CTX or 0.6/zg 
activated PTX, 5 x 106 cpm [32p]NAD and 5-10 gtg of protein homo ge- 
hated. The final incubation volume was in both cases 60/4. After 
incubation for 30 min at 32°C the reactions were stopped by adding 
1 ml of 20% ice-cold trichloroacetic a id. After standing on ice for 10 
rain the mixture was centrifuged in a table top centrifuge at 1200 x g 
for 30 rain at 4°C. The resulting pellets were washed with ether, resus- 
pended in 20/zl Laemmli's ample buffer [24] at room temperature and 
loaded onto 12.5% SDS-polyacrylamide g ls; electrophoresis was per- 
formed according to Laemmli. Autoradiography was performed on the 
dried SDS gels by exposing Dupont (Cronex 4 NIF 100) films. 
2.6. Immunoblotting 
The cell pellets were homogenized in buffer (50 mM Tris-HC1, pH 
7.5, 5 mM EDTA, 5 mg/ml soybean trypsin inhibitor, 0.1 mM phen- 
ylmethanesulfonyl fluoride, 2 mg/ml aprotinin, 2 mg/ml leupeptin, 
1 mg/ml benzamidin) by freezing in liquid nitrogen and thawed at 32°C 
for three times. Nuclei and unbroken cells were pelleted by centrifuga- 
tion at 500 × g for 2 min, and the resulting supernatant was then spun 
at 50,000 × g for 15 min. Membrane pellets were resuspended in homog- 
enizing buffer at a concentration of 1-2 mg/ml of protein. 
10 pg of membrane protein was fractionated by SDS-PAGE and 
transferred to nitrocellulose as described by Towbin et al. [25]. The 
filters were incubated either with anti-Gas or anti-G~ antibody, and the 
immunoreactive bands were detected by use of a horseradish peroxi- 
dase-coupled secondary antibody and the enhanced chemioluminis- 
cence (ECL) system from Amersham Corp. 
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Fig. 1. Decreased AC activity in cells incubated with media supple- 
mented with h-LPDS plus lovastatin. Cells were cholesterol-depleted by 
preincubation i medium supplemented with 10% h-LPDS for 24 h. 
Then, the media were removed and replaced with fresh media with 10% 
h-LPDS containing increasing concentrations of lovastatin for the fol- 
lowing 48 h. Data shown are the means + S.E.M. of four independent 
experiments performed in duplicate. *0,05 > P > 0.01; **0.01 > P > 0.00l, 
2. 7. Measurements of cell protein 
Proteins were determined essentially as described by Bradford [26], 
using bovine serum albumin as standard. 
3. Resu l ts  
3.1. Effect of  lovastatin on A C activity 
Lovastatin, a competitive inhibitor of HMG-CoA reductase, 
was studied for its effects on basal AC activity in GH4C1 cells. 
As shown in Fig. 1, addition of lovastatin to the cultures for 
48 h markedly decreased the activity of AC. The inhibition was 
dose-dependent, being maxime at a concentration of 30/,tM. 
Treatment of GH4C1 cells for 24 or 48 h with this inhibitor did 
not alter their viability; the protein content of each plate com- 
pared with untreated cells was not modified at 24 h and slightly 
decreased at 48 h (data not shown). It is important o remark 
that the drug was added at the end of the proliferating phase. 
These results suggest hat the observed effects on AC caused 
by lovastatin are due to the decrease in mevalonate production 
which is a consequence of HMG-CoA reductase inhibition. 
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Fig. 2. Effect of lovastatin on ADP-ribosylation of G~s and Ga~. Ceils were treated as indicated in Fig. 1. CTX and PTX-catalyzed ADP-ribosylation 
of Gs~ and G~ respectively was assayed as described in section 2. Data shown are the means + S.E.M. of four independent experiments performed 
in duplicate. *0.05 > P > 0.01; ***P < 0.001. Representative autoradiogram bands showing 32P-labeled ~-subunits appears at the right of the plot. 
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Fig 3. Treatment with lovastatin decreased Ggs and G~ protein levels in plasma membranes. Membrane from cells treated as indicated in Fig. l 
were prepared, solubilized and polyacrylamide g lelectrophoresis, immunoblotting, and autoradiography carried out as described insection 2. Data 
shown are the means _+ S.E.M. of four independent experiments performed in duplicate. *0.05 > P > 0.01; **0.01 > P > 0.001. Representative 
immunoblot bands of both cz-subunits appears at the right of the plot. 
3.2. Effect of lovastatin on G-protein o~ subunits 
It is generally accepted that AC activity is highly dependent 
on the activated state of the ~-subunits of G S and G i proteins. 
One way to test the steady-state of these proteins is to ADP- 
ribosylate their ~ subunits with CTX or PTX respectively. As 
shown in Fig. 2, lovastatin decreased the amount of ADP- 
ribosylation i the CTX substrate (G~s) in a dose related man- 
ner, that correlated with the decrease in AC activity. By con- 
trast, the effect of lovastatin on the ADP-ribosylation of PTX 
substrates, which include G~, was very mild, the decrease at 
the highest dosis being only 15%. 
The amount of both G protein ~ subunits in the membrane 
of cells treated with lovastatin was determined by immunoblot- 
ting. As shown in Fig. 3, the presence of lovastatin produced 
a decrease in the amount of both proteins in the plasma mem- 
brane, being about 40% for G~s and 30% for Gcz~. 
3.3. Mevalonate suppresses the effect of lovastatin on AC and 
G-proteins 
The importance of mevalonate on AC activity on GHaC 1 
cells was tested irectly by examining the ability of exogenous 
mevalonate o overcome the effect of lovastatin on basal AC 
activity. Mevalonate was added toghether with lovastatin for 
the 48 h incubation. As shown in Fig. 4, exogenous mevalonate 
counteracted the effect of lovastatin on AC activity. Similarly 
to what occurs with AC activity mevalonate added to the 
media, counteracted the effect of lovastatin on ADP-ribosyla- 
tion of both Gas and G~i (Fig. 5), as well as on the amount of 
both proteins measured by immunoblotting (Fig. 6). 
4. Discussion 
The results of this study show that the HMG-CoA reductase 
inhibitor lovastatin decreases basal AC activity in GH4C~ cells. 
The effect was concentration dependent and was prevented by 
the addition of mevalonate. This clearly indicates that mevalo- 
nate availability is important for AC activity. Our data also 
indicate that suppression ofmevalonate synthesis decreases the 
amount of G~s and G~i in the cell membrane, as measured by 
both immunoblotting and ADP-ribosylation. This decrease was 
also dose dependent, parallel to the inhibition produced in AC 
activity and also reverted by the presence of mevalonate. 
Although none of the G-protein subunits contain regions 
that might obviously associate with a lipid bilayer, the hetero- 
trimer is bound to the plasma membrane due in part to the fact 
that the 7/-subunits are prenylated [5-8]. The carboxyl-terminal 
posttranslational modifications ofG-protein 7~-subunits are im- 
portant determinants of the subcellular location of the G-sub- 
units. The mutation of the modified cysteine into serine in 7/2 
redistributes the fl [27] and ~ [28] subunits from the membrane 
to the cytosol in transfected cells. The decrease in the amount 
of cz~ and ~i bound to the membrane in cells treated with lova- 
statin should be due, at least in part, to the lack of prenyl 
residues in the ? subunits. 
In addittion of their effects on cholesterol and mevalonate 
synthesis, lovastatin blocks the cell cycling in G1 and G2/M 
phases of cells grown in vitro [29-30] as well as suppresses 
growth of tumors in vivo [31]. We have found that when lova- 
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Fig. 4. Effect of mevalonate on AC activity in lovastatin-treated c lls. 
Cells were preincubated with medium supplemented with 10% h-LPDS 
for 24 h. The media were removed and replaced with fresh media with 
10% h-LPDS alone or 10% h-LPDS plus 30/IM lovastatin i  absence 
or presence of50 tiM mevalonate (MVA) for the following 48 h. Each 
bar represent the means + S.E.M. of duplicate determinations from 
four experiments. *0.01 > P > 0.001. 
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Fig. 5. The addition of mevalonate r vert he effect of lovastatin on 
ADP-ribosylation of Gc~+ and Gc~. CTX or PTX-catalyzed ADP- 
ribosylation of G~z+ and Gets, respectively were assayed in cells treated 
as described in Fig 4. Lov = 30/IM lovastatin; MVA -- 50 gtM mevalo- 
nate. Each bar represents he means + S.E.M. of four determinations 
carried out in duplicate. Representative autoradiogram bands showing 
32p-labeled G+~ and Gic~ proteins appears below the appropriate col- 
umns for each group. *0.05 > P > 0.01; ***P < 0.001. 
statin was added to cultures of GH4C 1 in media supplemented 
with h-LPDS in the exponential phase, the rate of growth was 
markedly decreased (data not shown). The actual mechanism 
by which lovastatin blocks mitogenesis not known, but inhi- 
bition of  isoprenylation of proteins, such as inhibition of far- 
nesylation of the oncogene product p21ras, has been proposed 
[32]. An activated mutant form of Gets has been identified in 
pituitary tumors and postulated to be an oncogen [33]. Re- 
cently, it has been shown that the effects of GTPase-deficient 
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Fig. 6. Recovery of G~+ and G0~ i protein levels in membranes of lova- 
statin-treated cells by addition of mevalonate. Membranes from cells 
incubated as indicated in Fig. 4 were prepared, electrophoresed and 
transferred to nitrocellulose membranes as described in section 2. The 
histogram and the immunoblots shown are of membranes prepared 
from cells incubated as indicated in Fig. 4. Lov = 30 ItM lovastatin; 
MVA = 50/zM mevalonate. Values shown are the means + S.E.M. of 
four independent determinations performed in duplicate. Panels below 
each column are representative immunoblots using the indicated anti- 
bodies. **0.01 > P > 0.001. 
forms of Gas found in human secretory tumors constitutively 
stimulate immediate arly genes, thus supporting their onco- 
genic potential [34]; these effects are clearly mediated by the 
cAMP/PKA pathway and are therefore distinct from those 
exerted by the Ras oncogene. Although we do not know if the 
cAMP pathway exerts any influence on the rate of growth of 
the pituitary somato-mamotroph cell lines, like GHaC ] cells, 
our data show that lovastatin can decrease the AC activity by 
decreasing the amount of Gas in the membrane and so de- 
creases any proliferating effects mediated through the cAMP 
pathway by G~+ oncogenic proteins. 
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